Supriya Lifescience (Mid Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Supriya Lifescience Limited |
|||
|
Price: ₹955.20 (-2.25%) | ||
| 52 Week Low: ₹545.50 52 Week High: ₹1,085.00 |
|||
| Market Capital: 5,173.83 Crore (Mid-cap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Supriya Lifescience Share Price Target For 2026
- 1.1.1: Supriya Lifescience Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Supriya Lifescience Share Price Target For 2027
- 1.2.1: Supriya Lifescience Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Supriya Lifescience Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Supriya Lifescience Brief Company Overview
- 4: Supriya Lifescience Financial Performance
- 4.0.1: Is Supriya Lifescience A Good Buy For Long Term?
Supriya Lifescience, a Mid Cap company in the Biotechnology Industry has delivered 283.4% returns in 3-year showing 33.2% quarterly revenue growth with 21.7% profit margin, making it a potential Multibagger.
To predict the Supriya Lifescience's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Supriya Lifescience Share Price Target For 2026
The line chart displays the monthly closing prices of Supriya Lifescience with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Supriya Lifescience shares in 2026, see the table below.
Supriya Lifescience Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1112.58 (+16.47%) | Volatility: ATR T2 |
| 2026 Target 2 | 1085.45 (+13.63%) | Volatility: BB Upper |
| 2026 Target 1 | 1049.63 (+9.88%) | Volatility: ATR T1 |
| Current Price | 955.20 | Supriya Lifescience's share price as of 15 Jun 2026 |
| Stop Loss 1 | 939.48 (-1.65%) | Trend: EMA9 |
| Stop Loss 2 | 878.91 (-7.99%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 860.77 (-9.89%) | Volatility: ATR S1 |
Short-Term Technical Outlook
Current Technical Position: Supriya Lifescience is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹745.38 serves as the nearest technical reference point.
Historical Returns: 3-month: +66.47% | 6-month: +32.2% | 1-year: +41.71%
Supriya Lifescience Share Price Target For 2027
The line chart displays the monthly closing prices of Supriya Lifescience with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Supriya Lifescience shares in 2027, see the table below.
Supriya Lifescience Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 1112.58 (+16.47%) | Volatility: ATR T2 |
| 2027 Target 2 | 1085.45 (+13.63%) | Volatility: BB Upper |
| 2027 Target 1 | 1049.63 (+9.88%) | Volatility: ATR T1 |
| Current Price | 955.20 | Supriya Lifescience's share price as of 15 Jun 2026 |
| Stop Loss 1 | 939.48 (-1.65%) | Trend: EMA9 |
| Stop Loss 2 | 878.91 (-7.99%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 860.77 (-9.89%) | Volatility: ATR S1 |
Long-Term Technical Outlook
52-Week Range Analysis: Supriya Lifescience is currently trading near its 52-week high of ₹1085, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +41.71% | 3-year: +283.42% | 5-year: +102.02%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Supriya Lifescience Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹955.20 | ||
| 2026 | ₹1,198.32 | +25.452261306533% | ₹1,216.29 |
| 2027 | ₹1,527.89 | +27.502670405234% | ₹1,550.81 |
| 2028 | ₹2,339.08 | +53.092172865848% | ₹2,374.17 |
| 2029 | ₹3,470.85 | +48.38526258187% | ₹3,522.91 |
| 2030 | ₹4,919.90 | +41.749139259835% | ₹4,993.70 |
| 2031 | ₹6,209.86 | +26.219232098213% | ₹6,303.01 |
| 2032 | ₹8,783.06 | +41.4373270895% | ₹8,914.81 |
| 2033 | ₹11,532.83 | +31.30765359681% | ₹11,705.82 |
| 2034 | ₹14,695.25 | +27.421023287432% | ₹14,915.68 |
| 2035 | ₹17,875.89 | +21.644000612443% | ₹18,144.03 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Supriya Lifescience Brief Company Overview
Supriya Lifescience Limited: A Leading Global Pharmaceutical Player Established in 1987, Supriya Lifescience Limited is a renowned pharmaceutical company headquartered in Mumbai, India. The company specializes in developing, manufacturing, and distributing a comprehensive...
range of bulk drugs and pharmaceutical chemicals worldwide. Their impressive product portfolio encompasses: Anti-allergic and anti-asthmatic medications Decongestants and analgesic/anti-pyretic/anesthetic drugs Anti-hypertensive and anti-malarial products Vitamins and xanthine derivatives Supriya Lifescience has earned a reputation for innovation and excellence in the pharmaceutical industry, with a strong commitment to providing high-quality, affordable healthcare solutions.Supriya Lifescience Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,961.76 Crore | Market valuation of Supriya Lifescience's shares. |
| Revenue (TTM) | 554.46 Crore | Total revenue generated by Supriya Lifescience over the past twelve months. |
| Net Income (TTM) | +120.41 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 26.79% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 21.71% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+33.2% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+213% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.76 | Company's total debt divided by total shareholder equity. |
| Total Debt | 5.77 Crore | Sum of Supriya Lifescience's current & long-term financial obligations. |
| Total Cash | 115.8 Crore | Total amount of liquid funds available to Supriya Lifescience. |
| Beta | 0.27 | Beta is less than 1 indicating that the Supriya Lifescience's price is less volatile than the market. |
Is Supriya Lifescience A Good Buy For Long Term?
Supriya Lifescience, a small-cap stock, has shown strong financial performance with a revenue of 554.46 Crore and a net profit of 120.41 Crore in the last 12 months. With a profit margin of 21.71%, the company has a stable financial position with manageable debt levels and substantial cash reserves. Its recent quarterly growth in revenue and earnings, coupled with impressive returns over the last year, indicates a positive outlook. Based on these factors, Supriya Lifescience appears to be a promising buy for long-term investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
